Analysts Anticipate arGEN-X BV (ARGX) to Post ($0.31) EPS
arGEN-X BV (NASDAQ:ARGX) has received a consensus broker rating score of 1.00 (Strong Buy) from the five analysts that cover the stock, Zacks Investment Research reports. Five research analysts have rated the stock with a strong buy recommendation.
Brokers have set a 1-year consensus target price of $91.67 for the company and are expecting that the company will post ($0.31) EPS for the current quarter, according to Zacks. Zacks has also given arGEN-X BV an industry rank of 192 out of 265 based on the ratings given to related companies.
A number of analysts have issued reports on the company. Zacks Investment Research downgraded arGEN-X BV from a “hold” rating to a “sell” rating in a report on Wednesday, March 7th. JMP Securities lifted their price target on arGEN-X BV from $74.00 to $87.00 and gave the stock an “outperform” rating in a report on Monday, January 29th. Finally, Piper Jaffray Companies lifted their price target on arGEN-X BV to $100.00 and gave the stock an “overweight” rating in a report on Tuesday, December 19th.
Shares of arGEN-X BV (ARGX) opened at $79.71 on Tuesday. arGEN-X BV has a fifty-two week low of $17.33 and a fifty-two week high of $87.00.
About arGEN-X BV
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for arGEN-X BV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for arGEN-X BV and related companies with MarketBeat.com's FREE daily email newsletter.